Abstract:Hepatic fibrosis is an essential pathology of multiple chronicliverdiseases. The aim of this study was to investigate the role of miR-301a-3p in hepatic fibrosis. We found that miR-301a-3p was upregulated in hepatic fibrosis patients and in culture-activated human hepatic stellate cells (HSCs). Interestingly, miR-301a-3p expression was increased in hepatic fibrosis progression mice while decreased in hepatic fibrosis recovery mice, indicating that miR-301a-3p may participate in the hepatic fibrosis pathology. Functionally, the effects of miR-301a-3p both on hepatic fibrosis progression and regression were assessed in vivo. Inhibiting miR-301a-3p amelioratedmouse liver fibrogenesis and collagen deposition and suppressed HSC activation and fibrogenic factor expression. Whereas, in hepatic fibrosis regression, upregulating miR-301a-3p impaired mouse hepatic fibrosis recovery by inducing HSC activation and triggering inflammation. Consistently, gain-of-function and loss-of-function analysis of miR-301a-3p were performed to evaluate its effects on human HSCs LX-2 cell. We found that suppressing miR-301a-3p inhibited LX-2 cell activation and proliferation, and induced LX-2 cell apoptosis, accompaniedby decreased fibrotic mediators expression. Collectively, these findings suggest miR-301a-3p drives liver fibrogenesis and HSC activation in hepatic fibrosis. Mechanistically, we demonstrated miR-301a-3p binds directly to phosphatase and tensin homolog (PTEN) by luciferase reporter analysis, pull-down, and RIP assay. Indicating that miR-301a-3p plays a critical rolein promotingliverfibrogenesis viamodulating the PTEN/platelet derived growth factor β (PDGFR-β) pathway. In conclusion, our findings demonstrate that miR-301a-3p expression is closely correlated with hepatic fibrosis pathology, and that enhancing miR-301a-3p maintains the HSC profibrogenic phenotype, triggers inflammatoryresponses, promotes fibrogenic factor production, and further exacerbates liver fibrogenesis. These findings suggest that miR-301a-3p may serve as a promising diagnostic and prognosis biomarker for hepatic fibrosis treatment.

The activation of M<sub>3</sub> muscarinic receptor reverses liver injury via the Sp1/lncRNA Gm2199/miR-212 axis

The activation of M<sub>3</sub> muscarinic receptor reverses liver injuryvia the Sp1/lncRNA Gm2199/miR-212 axis

Mir-301A-3p Promotes Hepatic Stellate Cells Activation and Liver Fibrogenesis Via Regulating PTEN/PDGFR-β.

MicroRNA-101 Suppresses Liver Fibrosis by Downregulating PI3K/Akt/mTOR Signaling Pathway

MiR-542-3p controls hepatic stellate cell activation and fibrosis via targeting BMP-7.

LncRNA-MEG3 inhibits activation of hepatic stellate cells through SMO protein and miR-212

The Mir‐455‐3p/hdac2 Axis Plays a Pivotal Role in the Progression and Reversal of Liver Fibrosis and is Regulated by Epigenetics

LncRNA MEG3 reverses CCl4-induced liver fibrosis by targeting NLRC5

MiR-22-3p and Mir-29A-3p Synergistically Inhibit Hepatic Stellate Cell Activation by Targeting AKT3

MicroRNA-212 activates hepatic stellate cells and promotes liver fibrosis via targeting SMAD7.

C1q/tumor Necrosis Factor-Related Protein-3 Acts As a Target Treating Hepatic Fibrosis

A Role of Microrna‐370 in Hepatic Ischaemia‐reperfusion Injury by Targeting Transforming Growth Factor‐β Receptor II

MiR-552-3p Regulates Multiple Fibrotic and Inflammatory genes Concurrently in Hepatic Stellate Cells Improving NASH-associated Phenotypes

Mir-345–5P Curbs Hepatic Stellate Cell Activation and Liver Fibrosis Progression by Suppressing Hypoxia-Inducible Factor-1Alpha Expression

Integration of high‑throughput data of microRNA and mRNA expression profiles reveals novel insights into the mechanism of liver fibrosis.

The role of the miR-31/FIH1 pathway in TGF-β-induced liver fibrosis.

miR-140-5p attenuates hepatic fibrosis by directly targeting TGFβR1

MicroRNA-195-3p promotes hepatic stellate cell activation and liver fibrosis by suppressing PTEN expression

Identification Lncrna LOC102551149/miR‐23a‐5p Pathway in Hepatic Fibrosis

WITHDRAWN: NS3TP1 promotes liver fibrosis by activating HSCs through TGFβ1/Smad3 and NF-κB/NLRP3 inflammasome signaling pathways

Activation of the Mir-34A/sirt1/p53 Signaling Pathway Contributes to the Progress of Liver Fibrosis Via Inducing Apoptosis in Hepatocytes but Not in HSCs.